Xequel Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
7
Active:0
Completed:5
Trial Phases
3 Phases
Phase 1:4
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (57.1%)Phase 2
2 (28.6%)Phase 3
1 (14.3%)Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease
Phase 1
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: iNexin™ (2.0% aCT1)Drug: Vehicle (eye drop formulation without aCT1)Drug: iNexin™ (0.4% aCT1)Drug: iNexin™ (0.08% aCT1)
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Xequel Bio, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05031806
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Study of the Efficacy and Safety of Granexin® Gel to Improve Burn Wound Healing
Phase 2
Withdrawn
- Conditions
- Second Degree BurnThermal Burn
- Interventions
- Drug: Vehicle gel
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Xequel Bio, Inc.
- Registration Number
- NCT04684121
Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy
Phase 1
Completed
- Conditions
- Wound Heal
- Interventions
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Xequel Bio, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04473859
- Locations
- 🇨🇭
Swiss Pharma Contract Ltd, Allschwil, Switzerland
A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery
Phase 2
Completed
- Conditions
- ScarringMammoplastyScarBreast Reconstruction
- Interventions
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Xequel Bio, Inc.
- Target Recruit Count
- 184
- Registration Number
- NCT04331080
- Locations
- 🇺🇸
Private Clinic- David Kulber, Los Angeles, California, United States
🇺🇸Pasadena Surgeons, Pasadena, California, United States
🇺🇸Universal Axon Clinical Research, Doral, Florida, United States
A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Xequel Bio, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT02667327
- Locations
- 🇺🇸
New Hope Podiatry Group, Inc., Los Angeles, California, United States
🇺🇸Integral - Clinical Trials Solutions, Doral, Florida, United States
🇺🇸Direct Helpers Research Center, Hialeah, Florida, United States
- Prev
- 1
- 2
- Next
News
No news found